Nuances and complexities of cell death control

Abstract

© 2017 Dr. Hui San ChinThe success of targeting the pro-survival protein BCL2 with venetoclax in many patients with high-risk chronic lymphocytic leukemia validates the power of directly targeting BCL2 in a previously untreatable malignancy. However, primary or secondary resistance to venetoclax is an emerging problem. My PhD studies to better understand and explore potential avenues by which cells can become resistant to BCL2 inhibitors like venetoclax have uncovered potential targets for clinical validation and, importantly, revealed the previously unappreciated complexities of cell death control